Your browser doesn't support javascript.
loading
Determination of asundexian and its metabolite M-10 in human plasma by LC-MS/MS.
Fiebig, Lukas; Helmes, Sabine; Kaiser, Michael; Werner, Daniel.
Afiliação
  • Fiebig L; Pharmaceuticals, Drug Metabolism & Pharmacokinetics, Research & Development, Bayer AG, Wuppertal, D-42096, Germany.
  • Helmes S; Pharmaceuticals, Drug Metabolism & Pharmacokinetics, Research & Development, Bayer AG, Wuppertal, D-42096, Germany.
  • Kaiser M; Pharmaceuticals, Drug Metabolism & Pharmacokinetics, Research & Development, Bayer AG, Wuppertal, D-42096, Germany.
  • Werner D; Pharmaceuticals, Drug Metabolism & Pharmacokinetics, Research & Development, Bayer AG, Wuppertal, D-42096, Germany.
Bioanalysis ; 15(4): 197-206, 2023 Feb.
Article em En | MEDLINE | ID: mdl-37040422
Background: The authors present a validated method for the simultaneous quantification of asundexian (BAY 2433334) and its pharmacologically inactive major human metabolite M-10 from human plasma and its application in clinical study sample analysis. Materials & methods: Sample preparation was performed by protein precipitation followed by reverse phase HPLC and positive/negative ESI-MS/MS. Results: Assay working ranges were 0.5-500 ng/ml for asundexian and 5.0-5000 ng/ml for M-10. Validation results met the requirements of pertinent guidelines. In clinical study sample analysis, accuracy and precision acceptance criteria for analyzed quality control samples were met and incurred sample reanalysis was fulfilled. Conclusion: The method proved to be selective, specific, sufficiently sensitive, reproducible and robust for the analysis of samples obtained from clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasma / Espectrometria de Massas em Tandem Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasma / Espectrometria de Massas em Tandem Idioma: En Ano de publicação: 2023 Tipo de documento: Article